Navigation Links
Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Date:8/19/2007

and access to capital to fund future clinical trials for PDX or any of its other product candidates. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2006 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.

Note: The Allos logo is a trademark of Allos Therapeutics, Inc.


'/>"/>
SOURCE Allos Therapeutics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
2. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Landauer, Inc. (NYSE: ... environmental radiation measurement and monitoring, outsourced medical physics services ... will release financial results for the fiscal first quarter ... 2015. The Company will also host ... 2015 at 9:00 a.m. Central Time (10:00 a.m. Eastern ...
(Date:3/2/2015)...  Actavis plc (NYSE: ACT ) ... offerings of 14,513,889 Ordinary Shares at $288.00 per ... Series A, at $1,000.00 per share, each having ... The amounts sold include 1,319,444 Ordinary Shares and ... the exercise in full of the over-allotment option ...
(Date:3/2/2015)... Utah , March 2, 2015  BC ... Imaging Solutions, has acquired Eclipse Systems, a Nuclear ... service solutions. As part of their ongoing vision ... at an affordable rate, BC Technical continues to ... allows BC Technical to add valuable resources and ...
Breaking Medicine Technology:Landauer, Inc. Announces Date and Time for Announcement of Fiscal First Quarter 2015 Results and Conference Call 2Actavis Announces Closing of Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan 2Actavis Announces Closing of Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan 3Actavis Announces Closing of Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan 4Actavis Announces Closing of Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan 5Actavis Announces Closing of Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan 6Actavis Announces Closing of Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan 7Actavis Announces Closing of Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan 8BC Technical Acquires Eclipse Systems 2
(Date:3/2/2015)... NY (PRWEB) March 02, 2015 ... Administration (FDA) warned against the use of power ... and fibroid removal surgeries, insurer UnitedHealthCare is poised ... use of those devices. In a notification sent ... beginning in April, it would require pre-authorization for ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 ZoomCare ... to remake American healthcare. Zoom will expand its ... neighborhood clinics and advanced care studios delivering urgent ... emergency services, specialty care and outpatient surgery. With ... access to almost all healthcare needs outside of ...
(Date:3/2/2015)... York (PRWEB) March 02, 2015 ... at Recovery Unplugged™—will be delivering a plenary address ... Perspective on the Art of Healing and Recovery ... (NCAD) and Behavioral Healthcare Executive Summit (BHES).     , ... Mr. Supa’s songs have been recorded by some ...
(Date:3/2/2015)... NY (PRWEB) March 02, 2015 This year, ... March 2–8 and will provide opportunities for people across the ... ways to help people with MS live their best lives. ... made and to inspire others to join the Society’s vision ... sclerosis, an unpredictable, often disabling disease of the central nervous ...
(Date:3/2/2015)... 2015 Regulatory Compliance Associates® Inc. ... regulatory and technical consulting, announces Mr. Seyed Khorashahi ... , Before joining RCA, Mr. Khorashahi had ... in all aspects of developing safety-critical medical devices. ... (Medtronic), Regulatory Compliance Associates Inc., Baxter Healthcare, and ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 4Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 2Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 3Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2
... rates reach the highest levels in 16 years, a ... laid-off workersonly 9 percenttook up coverage under the Consolidated ... who also lose their health insurance would need substantial ... health insurance premiums, for their premium contributions to remain ...
... Incidents were reported by half of family caretakers surveyed in ... than half of family members looking after people with dementia ... British study finds. , Actual physical abuse was rare, being ... study. But the researchers, who published their findings in ...
... 22 The following is a statement from United ... Hearing Officer Ray Marshall ruled against a ... of the Service Employees International Union in 1921 that ... right to take over a local union. Even with ...
... T. Allison, FACHE, president/CEO of Baylor Health Care System ... the Texas Hospital Association,s Earl M. Collier Award for ... Award is the highest honor bestowed by THA. Allison ... Leadership Conference in Austin."Joel Allison exemplifies the leadership qualities ...
... MADISON, N.J., Jan. 22 At a meeting of its ... ) declared dividends on both the Common and Preferred Stock ... on the outstanding shares of Common Stock was declared payable ... close of business on February 13, 2009. In addition, ...
... WASHINGTON, Jan. 22 Speaker Nancy Pelosi released ... 36th Anniversary of Roe v. Wade:"On the 36th ... commitment to protecting a woman,s right to make ... just two days after swearing in a new ...
Cached Medicine News:Health News:Only about one of ten unemployed workers obtain COBRA coverage 2Health News:Many Alzheimer's Caregivers Admit to Abusive Behavior 2Health News:Many Alzheimer's Caregivers Admit to Abusive Behavior 3Health News:UHW Statement on Ray Marshall Trusteeship Recommendations 2Health News:Allison Honored with Hospital Association's Highest Award 2Health News:Allison Honored with Hospital Association's Highest Award 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: